These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2311332)

  • 1. Scintigraphic study of radiolabelled interferon-alpha in osteosarcoma patients.
    Diez RA; Perdereau B; Peter M; Dorval T; Gongora R; Falcoff ET
    Clin Pharmacokinet; 1990 Jan; 18(1):82-9. PubMed ID: 2311332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
    J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics of recombinant alpha 2-interferon (reaferon)].
    Kulakov VN; Pimenova GN; Matveev VA; Kobrinskiĭ GD; Kuznetsov VP
    Vopr Virusol; 1989; 34(2):183-6. PubMed ID: 2763512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interferons in the treatment of osteosarcoma.
    Whelan J; Patterson D; Perisoglou M; Bielack S; Marina N; Smeland S; Bernstein M
    Pediatr Blood Cancer; 2010 Mar; 54(3):350-4. PubMed ID: 19902521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series.
    Müller CR; Smeland S; Bauer HC; Saeter G; Strander H
    Acta Oncol; 2005; 44(5):475-80. PubMed ID: 16118081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
    Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
    J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma.
    Ohtomo K; Terui S; Yokoyama R; Abe H; Terauchi T; Maeda G; Beppu Y; Fukuma H
    J Nucl Med; 1996 Sep; 37(9):1444-8. PubMed ID: 8790189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma and interferon. Studies of human xenografts in the nude mouse.
    Brosjö O
    Acta Orthop Scand Suppl; 1989; 229():1-36. PubMed ID: 2494840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.
    Haria M; Benfield P
    Drugs; 1995 Nov; 50(5):873-96. PubMed ID: 8586031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide.
    Jia SF; An T; Worth L; Kleinerman ES
    J Interferon Cytokine Res; 1999 Jun; 19(6):617-24. PubMed ID: 10433362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
    de Wit R; Bakker PJ; Danner SA; Goudsmit J; Veenhof KH
    Int J STD AIDS; 1990 Jul; 1(4):256-8. PubMed ID: 2088534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells.
    Manara MC; Serra M; Benini S; Picci P; Scotlandi K
    Int J Oncol; 2004 Feb; 24(2):365-72. PubMed ID: 14719113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of growth inhibiting effect of natural and recombinant interferon-alpha on human osteosarcomas in nude mice.
    Bauer HC; Brosjö O; Strander H
    J Interferon Res; 1987 Aug; 7(4):365-9. PubMed ID: 3478420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: Comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response.
    Ilhan IE; Vural G; Berberoglu S; Kapucuoglu N; Cila A; Eke S
    Pediatr Hematol Oncol; 2005 Mar; 22(2):153-62. PubMed ID: 15805001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local tumour resection in interferon treated osteosarcoma patients.
    Nilsonne U; Broström LA; Aparisi T
    Ann Chir Gynaecol; 1995; 84(1):63-70. PubMed ID: 7645912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
    Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
    J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
    Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
    Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.